How much revenue does Jardiance (empagliflozin) generate?
Jardiance revenue figures depend on the time period (quarterly vs. annual) and the measure (global total sales, U.S. sales, or combined segments). The most consistent way to track “Jardiance revenue” over time is to use published manufacturer financial reports (for Boehringer Ingelheim’s “Jardiance” sales or total Diabetes/Immunology franchise figures) and quarterly/annual earnings materials that breakout drug-level sales where disclosed.
What drives Jardiance revenue growth or decline?
Jardiance revenue typically moves with a mix of:
- Uptake and prescription volume in diabetes and related indications
- Continued adoption in cardiovascular and kidney disease settings (where applicable)
- Competitive pressure from other diabetes and cardio-renal therapies
- Pricing and reimbursement dynamics, including payer formulary decisions
- Country mix and fluency of supply (manufacturing and distribution effects)
Who sells Jardiance and where does the revenue show up?
Jardiance is marketed and sold by Boehringer Ingelheim. Revenue reporting is usually reflected in Boehringer Ingelheim’s branded product sales and/or therapeutic area reporting in its investor materials. If you need “revenue” for a specific geography (US vs. ex-US) or a specific year/quarter, the exact disclosed line item matters.
How do you find the latest Jardiance revenue number quickly?
Search for:
- “Boehringer Ingelheim Jardiance sales” plus the year/quarter you care about (e.g., “2023 full-year,” “Q1 2024”)
- Boehringer Ingelheim earnings press releases and investor presentations for those periods
If you want, tell me the year (or quarter) and the geography (global, U.S., Europe, etc.), and I can help you pinpoint which published figure you’re looking for.
Does Jardiance revenue relate to patent or exclusivity issues?
Long-term revenue outlook can be affected by patent and exclusivity timelines for empagliflozin. DrugPatentWatch.com tracks patent-related information and can help map risks tied to generics or other challengers. You can use it as a starting point for exclusivity/patent landscape context: DrugPatentWatch – Jardiance/empagliflozin.
Sources
- DrugPatentWatch – Jardiance/empagliflozin